Cardiology Research and Practice

Review Article

A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension

Table 1

Baseline characteristics of studies incorporated in the meta-analysis.


First author	Research design	E/C	Men, m (%)	Age (y)	BMI (kg/m²)	Baseline SBP (mmHg)	Baseline DBP (mmHg)	Duration	Number

Williams et al. [10]	Multicenter, randomized, double-blind, active-controlled, parallel-group study	LCZ696 200 mg, qd	52	68.2 ± 5.73	28.6 ± 4.47	160.4 ± 12.32	85.8 ± 8.62	52 weeks	229
Williams et al. [10]		Olmesartan 20 mg, qd	52.4	67.2 ± 5.97	29.1 ± 4.9	160.8 ± 15.6	85.8 ± 8.6	52 weeks	225

Izzo et al. [11]	Multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group study	LCZ696 400 mg, qd	50	61.2 ± 10.6	29.3 ± 5.5	159.6 ± 7.0	90.9 ± 8.9	8 weeks	142
Izzo et al. [11]		Valsartan 320 mg, qd	58	62 ± 11.5	30 ± 5.3	160.0 ± 7.3	90.2 ± 9.4	8 weeks	143
Wang et al. [12]	Multicenter, randomized, double-blind, crossover study	LCZ696 400 mg qd	64	55.7 ± 12.5	26.4 ± 3.8	147 ± 9.7	147.5 ± 12.1	4 weeks	36
Wang et al. [12]	Multicenter, randomized, double-blind, crossover study	Valsartan 320 mg, qd	64	58.9 ± 7.5	25.7 ± 2.9	90.2 ± 6.9	90.4 ± 7.2	4 weeks	36

Supasyndh et al. [13]	Multicenter, randomized, double-blind, active-controlled, parallel-group study	LCZ696 200 mg, qd	48	70.5 ± 4.67	24.3 ± 3.15	160.5 ± 8.41	84.6 ± 9.74	14 weeks	296
Supasyndh et al. [13]		Olmesartan 20 mg, qd	52.1	70.9 ± 4.67	24.6 ± 3.24	160.0 ± 7.99	85.2 ± 9.83	14 weeks	292
Schmieder et al. [14]	Multicenter randomized, double-blind, double-dummy, active-controlled, parallel group study	LCZ696 400 mg, qd	64.9	60.5 ± 7.8	28.1 ± 4.5	155.3 ± 9.0	92.7 ± 8.8	52 weeks	57
Schmieder et al. [14]		Olmesartan 40 mg, qd	70.2	59.2 ± 13.1	28.6 ± 3.9	155.0 ± 9.1	91.7 ± 8.7	52 weeks	57
Huo et al. [15]	Multicenter, randomized, double-blind, active-controlled, parallel-group study	LCZ696 200 mg, qd	52.6	57.5 ± 10.17	26.4 ± 3.91	158.0 ± 7.15	90.7 ± 9.37	8 weeks	479
		LCZ696 400 mg, qd	51.5	58.1 ± 9.71	26.3 ± 3.56	157.9 ± 6.73	89.8 ± 9.46		472
		Olmesartan 20 mg, qd	53.9	57.4 ± 10.14	26.4 ± 3.92	158 ± 6.53	90.8 ± 9.57		484

Cheung et al. [16]	Multicenter, randomized, double-blind, active-controlled, parallel-group study	LCZ696 200 mg, qd	51.6	57.1 ± 10.19	30.5 ± 5.86	157.1 ± 9.54	90.4 ± 10.24	8 weeks	188
Cheung et al. [16]		Olmesartan 20 mg, qd	50.8	58.0 ± 9.09	30.6 ± 5.09	157.8 ± 10.17	912 ± 8.89	8 weeks	187
Ruilope et al. [17]	Multicenter, randomized, double-blind, placebo- and active-controlled, parallel group, dose range study	LCZ696 100 mg, qd	61	53 ± 10.4	N/A	154.9 ± 11.89	99.9 ± 3.62	8 weeks	156
		LCZ696 200 mg, qd	54	54 ± 9.7		156.8 ± 11.98	99.9 ± 4.06		169
		LCZ696 400 mg, qd	56	52 ± 10.9		156.3 ± 12.32	100.4 ± 4.06		172
		Valsartan 80 mg qd	58	53 ± 9.6	N/A	154.8 ± 10.53	99.5 ± 4.10		163
		Valsartan 160 mg qd	59	53 ± 9.7		155.3 ± 10.79	99.8 ± 4.41		166
		Valsartan 320 mg qd	60	53 ± 10.1		156.0 ± 11.48	99.5 ± 3.63		164